Lymphocyte and Cytokine Disturbances in Polymyalgia Rheumatica (TENOR-IMMUNO)

Regional University Hospital Center (CHRU)

Status: Completed

Conditions: Polymyalgia Rheumatica

Treatments: Drug: tocilizumab

Study type: Observational

Funder types: Other

Identifiers

NCT02888496

TENOR-IMMUNO

Details and patient eligibility

About

Pathophysiology of polymyalgia rheumatica (PMR) is ill defined. This study aims at characterizing immunological abnormalities in PMR patients, and to assess the effects of tocilizumab therapy on this abnormalities.

Full description

Comparison of PMR patients and matched control subjects.

Enrollment: 40 patients

Sex: All

Ages: 18 to 85 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• PMR patient included in the TENOR study with samples available

Exclusion criteria

• Patient not included in the TENOR study

Trial design

40 participants in 2 patient groups

PMR patients

Description:

Patients included in the clinical trial TENOR (prospective open-labeled study of tocilizumab in treatment-naïve PMR patients)

Treatment:

Drug: tocilizumab

Healthy controls

Description:

Matched to PMR patients for sex and age, exclusion of any autoimmune, inflammatory, neoplastic and chronic infectious disease